BAFF is increased in renal transplant patients following treatment with alemtuzumab (scientific article published on 12 June 2009)

Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy

Q33365360

High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura

Q33373525

Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients

Q33375949

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

Q33928629

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

Q34108411

BAFF AND APRIL: a tutorial on B cell survival

Q34994661

Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus

Q35953373

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

Q36375661

Alemtuzumab (Campath-1H): a systematic review in organ transplantation

Q36491577

B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling

Q36791432

Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion

Q36934308

B cells flying solo.

Q37049026

TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties

Q37178196

Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells

Q42079747

Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.

Q42636572

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

Q43050637

T cell costimulation by the TNF ligand BAFF.

Q43803679

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

Q44461489

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Q44514934

Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction

Q45072989

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

Q46001110

Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin

Q46250074

Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells.

Q46569157

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

Q46726060

T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.

Q46900319

BAFF production by antigen-presenting cells provides T cell co-stimulation.

Q51025017

Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.

Q51905201

In vitro and in vivo activation induces BAFF and APRIL expression in B cells.

Q52922658

VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF.

Q52929509

B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.

Q54550690

Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus

Q57332092

Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs

Q57702564

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients

Q61651688

The role of BAFF in B-cell maturation, T-cell activation and autoimmunity

Q77689779

Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia

Q78116391

Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid

Q79653590

BAFF overexpression is associated with autoantibody production in autoimmune diseases

Q80367249

Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome

Q81892161

Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab

Q83149414

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

1835-1845

P577

publication date

2009-06-12

P1433

published in

American Journal of Transplantation

Q4744273

P1476

title

BAFF is increased in renal transplant patients following treatment with alemtuzumab

P478

volume

Reverse relations

cites work (P2860)

Q91112563	Advances in T follicular helper and T follicular regulatory cells in transplantation immunity
Q38544529	Advances in pharmacotherapy to treat kidney transplant rejection
Q86254890	Alemtuzumab induction and antibody-mediated rejection in kidney transplantation
Q43970258	Alemtuzumab induction in deceased donor kidney transplantation
Q50963419	An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.
Q39101892	B Cell Immunity in Solid Organ Transplantation.
Q36432935	B Cells, Antibodies, and More
Q86421442	B cell modulation in transplantation
Q42221525	B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells.
Q38050398	B cells and antibodies in multiple sclerosis pathogenesis and therapy
Q37782255	B cells and transplantation tolerance
Q64996252	B-Cell Activating Factor Predicts Acute Rejection Risk in Kidney Transplant Recipients: A 6-Month Follow-Up Study.
Q42038591	B-cell tolerance in transplantation: is repertoire remodeling the answer?
Q34159016	B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.
Q89129026	Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial
Q26829578	Biologics in organ transplantation
Q47198559	Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity
Q36134073	Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients
Q37700827	Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection
Q44433786	Delayed allograft inflammation following alemtuzumab induction for kidney transplantation
Q34841849	Diagnosis and management of antibody-mediated rejection: current status and novel approaches
Q28294329	Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection
Q45444391	Elevated serum levels of B-cell activating factor in pediatric renal transplant patients
Q58122073	IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade
Q37811507	Immunoregulation and Tolerance
Q37996078	Induction therapy in renal transplant recipients: how convincing is the current evidence?
Q35418255	Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy
Q37993873	Lymphodepletion and homeostatic proliferation: implications for transplantation
Q38118743	Lymphodepletional strategies in transplantation.
Q37894733	Monitoring tolerance and rejection in organ transplant recipients.
Q33891669	Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.
Q36769110	Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients
Q40630490	Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.
Q33755462	Prevention trumps treatment of antibody-mediated transplant rejection
Q84588320	Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation
Q52793674	Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings.
Q53459320	Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.
Q38187176	Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy
Q37033965	Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients
Q50955240	Soluble BAFF Cytokine Levels and Antibody-Mediated Rejection of the Kidney Allograft.
Q38750505	Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation
Q51010023	The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
Q34106158	The generation and maintenance of serum alloantibody.
Q33891696	The role of B cells in solid organ transplantation.
Q37854490	Tolerance in clinical transplantation: progress, challenge or just a dream?
Q36102133	Tolerogenic therapies in transplantation.
Q91554792	Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation
Q26829817	Transplantation tolerance and its outcome during infections and inflammation
Q35235728	p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression

P356	DOI	10.1111/J.1600-6143.2009.02710.X
P932	PMC publication ID	4876605
P698	PubMed publication ID	19522878
P5875	ResearchGate publication ID	26288739